24/7 Market News Snapshot 04 March, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

March 4, 2025

DENVER, Colo., 04 March, 2025 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has recently captivated investor interest as its stock price surged significantly in pre-market trading, reaching approximately $0.928—a notable increase of 6.67% from the previous close of $0.870. The trading activity reflects robust engagement as evidenced by a current volume of 1.61 million shares, indicative of a positive market sentiment that may stem from recent developments related to the company’s pioneering research. Traders are advised to observe key resistance levels around the psychological threshold of $1.00, while support appears to be anchoring near the prior close, suggesting a strong potential for further upward momentum if sustained high volumes persist.

In tandem with this market activity, Hoth Therapeutics has announced significant breakthroughs in its preclinical research regarding Glial Cell Line-Derived Neurotrophic Factor (GDNF), showcasing its potential as a revolutionary treatment for obesity. Findings from advanced GDNF-transgenic models demonstrate that GDNF significantly boosts metabolism, enhances fat burning, and improves insulin sensitivity. The study highlights that GDNF-transgenic mice experienced noteworthy weight and fat reduction, even under high-fat dietary conditions, without necessitating caloric restriction.

Additionally, GDNF is shown to lower serum leptin levels, indicating improved metabolic health and greater glucose tolerance. CEO Robb Knie commented on these transformative findings, emphasizing GDNF’s potential to significantly alter obesity treatment paradigms by enhancing the body’s natural capacity for energy management rather than merely suppressing appetite.

Hoth Therapeutics is committed to advancing its GDNF-based therapies through cutting-edge delivery methods such as recombinant protein technology and gene therapy. As the company progresses towards further preclinical and clinical studies, it remains focused on revolutionizing obesity treatment and improving health outcomes for millions affected by obesity-related ailments.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.